life sciences in alberta
TRANSCRIPT
Life sciences in Alberta State of the industry 2015 1
Life sciences in AlbertaState of the industry 2015
2
Table of contents
Executive summary .....................................................1
Background and methodology ....................................2
Overview of companies ..............................................3
Research and development spending ..........................9
Human resources ......................................................10
Revenue ...................................................................12
Financing ..................................................................14
Issues facing the industry ..........................................16
Need more information? ...........................................21
Life sciences in Alberta State of the industry 2015 1
Executive summary
Alberta’s life sciences industry continues to be a major growth, diversification, employment and innovation engine for the province of Alberta.
The BioAlberta State of the industry report is a biennial survey of life sciences companies and executives in Alberta. It was developed to review the outlook for the province’s life sciences industry based on the current status of trends related to the industry’s nature, health, productivity and economic contribution, in addition to its capacity and track record for innovation.
Alberta’s life sciences industry continues to be a major growth, diversification, employment and innovation engine for the province of Alberta. With more than $1 billion in revenues generated by Alberta companies and 4,600 employees, the industry has demonstrated strong performance and continued positive momentum. The industry is comprised of a significant group of mature companies that have generated global revenues from their products and services, combined with a large number of emerging and smaller high-growth companies that expect to be major contributors of innovation, jobs and economic activity.
The industry invests a significant amount in research and development and the commercialization of new technologies is a goal almost all companies in the industry share.
The industry in Alberta continues to suffer from the difficulty of accessing meaningful amounts of investment capital. Financing from all sources continues to be in very short supply. This includes: institutional investors, private equity, venture capital, initial public offerings and other risk capital investors, especially for early-stage, emerging and high growth life sciences companies. The industry is also challenged with filling highly specialized technical positions such as chief technology officers and senior business development executives.
The types of companies that make up the life sciences industry also continue to evolve, featuring a continued increase in medical technology and device companies and a decrease in the number of human therapeutic development companies. There also continues to be a strong sub-sector of agricultural based companies along with functional ingredient and natural foods product companies.
The industry takes advantage of the great work in research at the province’s world-class post-secondary institutions.
Overall, the industry is characterized by companies with a high level of innovation, commercialization activity, new company creation, growth in employment, and growing revenues. It also provides diversification for the Alberta economy.
2
Background and methodology
The analysis in this report is intended to stimulate dialogue, provide a current snapshot of the industry and offer directional support for business leaders and government agencies. Our long-term objective is to help the life sciences industry in Alberta grow.In the spring of 2015, BioAlberta and Deloitte LLP (Deloitte) surveyed leaders of life sciences companies located in Alberta. Those surveyed represent businesses from small start-ups to large public companies, and include research and development companies, manufacturers, service companies, consultants and distributors of life sciences products.
The life sciences industry includes companies and organizations that:
• Use biotechnology or biological processes to develop products that improve health and well-being
• Develop applications to improve the diagnosis, prevention, and treatment of disease
• Create new agricultural alternatives
• Revolutionize traditional industry sectors such as oil and gas or information technology
This year’s report includes life sciences companies and organizations active in the following sectors:
• Agricultural biotechnology
• Environmental
• Health biotechnology and pharmaceuticals
• Industrial biotechnology and bioprocessing (also referred to as biofuels, biorefining, clean technology)
• Medical technology and devices
• Natural health products and functional ingredients
The intent of this report is to review and communicate the state of the life sciences industry in Alberta. Survey respondents provided feedback on the current status of their company’s products, positions and growth expectations. The survey was distributed electronically to more than 200 life sciences company representatives. Partial or complete results were compiled from 137 of these companies for a response rate slightly higher than 69%. To supplement the resulting data, information from other surveys conducted by BioAlberta was used, in addition to information available in the public domain. In some cases, respondents chose not to answer all questions. Caution should therefore be used if extrapolating these results to the entire population of companies in the industry.
The analysis in this report is intended to stimulate dialogue, provide a current snapshot of the industry and offer directional support for business leaders and government agencies. Our long-term objective is to help the life sciences industry in Alberta grow.
Life sciences in Alberta State of the industry 2015 3
Year established
% o
f com
pani
es
Overview of companies
When was your company established?
Twenty-five percent of the companies in the industry were created in the past five years, indicating significant innovation and entrepreneurship in the sector. Another 25% have existed for more than twenty years, indicating a solid basis of sustainable businesses. Clearly, there is continued growth in the industry in addition to a core segment of mature companies.
25%
11%
17%
22%
25%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
1993 or earlier
1994 –1998
1999 –2003
2004 –2008
2009 –2014
4
Calgary region
Edmonton region
Other region
Medical technology and devices
58%
36%
7%
Health biotechnology and pharma
Agricultural biotechnology
Health IT
Environmental biotechnology
Industrial biotechnology and bioprocessing
Natural health products and functional ingredients
Other
Where in Alberta is your company located?
Consistent with prior State of the industry reports, most of Alberta’s life sciences companies (93.4%) are located in Calgary and Edmonton. The remainder are located in other cities such as Lethbridge, Red Deer and Lloydminster.
In which sub-sectors of the industry would your company be classified:
The two largest sectors in life sciences in Alberta are the medical technology and devices and the health biotechnology and pharma sectors, which combine to represent 69% of the industry. The medical technology and devices sector continues to be the highest growth area, growing from 38% of the industry in 2013 to 46% in 2015.
Note: the percentages in this chart sum to greater than 100% because many of the surveyed companies can be classified in multiple industries.
7%
58%
35%
17.5%
5.1%
4.3%
6.5%
10.2%
16.7%23.3%
45.9%
Life sciences in Alberta State of the industry 2015 5
Research and development
58%
36%
7%
Manufacturing
Consulting, contract research or other service provider
Distributor, wholesaler or retailer
Other
Research and development
58%
36%
7%
Product engineering
Product demonstration or prototype
Regulatory approval
Scale-up manufacturing
Marketed product
In which category(ies) would your company be classified?
Research and development continues to be the most significant category of companies (42%), followed by manufacturing (28%). There has been growth in manufacturing and consulting/service providers since the last survey in 2013.
In which phase of development is your lead health IT technology or product?
A significant number of products are currently in development (31%), which bodes well for the future potential for revenues, employment and the need for services in Alberta. In addition there is a significant segment of products in the marketplace (23%) generating revenues for companies based in Alberta.
3%9%
18%
28%
42%
23%
7%
7%
23%
9%
31%
6
Research and development
58%
36%
7%
Product engineering
Product demonstration or prototype
Regulatory approval
Scale-up manufacturing
Marketed product
Research and development
58%
36%
7%
Regulatory approval
Scale-up manufacturing
Marketed product
In which phase of development is your lead medical technology and devices technology or product?
Approximately 35% of medical technology and device companies have marketed products, 17% have a product in demonstration or prototype stage and 15% have a product in research and development.
In which phase of development is your lead agricultural biotechnology, natural health or functional ingredient technology or product?
The majority of companies (55%) in this subsector have marketed products, while 24% are in research and development. This provides both (1) the stability associated with a significant mature group of companies with the potential for growth and (2) innovation from the developing companies.
35%
9%
13%
17%
11%
15%
55%
10.5%
10.5%
24%
Life sciences in Alberta State of the industry 2015 7
Research and development
58%
36%
7%
Pilot plant or demonstration plant
Full scale plant
Research and development
58%
36%
7%
Pre-clinical trials
Phase 1
Phase 2
Marketed product
In which phase of development is your lead environmental biotech, industrial biotechnology, or bioprocessing technology or product?
The majority of companies in this subsector have a full scale commercialized plant and 29% have a pilot or demonstration plant. This is one of the more mature sub-sectors of the life sciences industry in Alberta, providing a stable and secure environment for companies to enter and grow.
For your health biotechnology and pharmaceuticals product, in which phase of development is your lead technology?
The structure of the industry is well balanced with both a significant portion of companies having marketed products, as well as a significant amount of products and technologies in research and development. The revenues from current products and services provide a return to investors and the products under development provide a pipeline of opportunities and growth for the future of the industry in Alberta.
57% 29%
14%
29%
17%
3%17%
34%
8
How would you classify your company in its lifecycle?
Emerging phase (radically new products with frequent changes; high technical uncertainty but broad R&D focus)
29.7%
Growth phase (gradual increase in process innovation; at least one stable, high-volume product design emerges)
45.1%
Maturity phase (mostly process innovation aimed at cost reduction; incremental product innovations)
25.2%
Total 100.0
The largest segment of companies (45%) classify themselves as in the growth phase while 30% classify themselves in the emerging phase. This indicates that many companies expect to be significantly larger in the future and are investing in technologies, innovation and their people in Alberta.
What phase do you expect your company to be in by 2016?
Emerging phase (radically new products with frequent changes; high technical uncertainty but broad R&D focus)
15.4%
Growth phase (gradual increase in process innovation; at least one stable, high-volume product design emerges)
59.3%
Maturity phase (mostly process innovation aimed at cost reduction; incremental product innovations)
25.3%
Total 100.0
With the expected increase in the future growth phase, these results indicate that the prospects for innovation and increased commercial activity in Alberta’s life sciences sector are very strong.
Life sciences in Alberta State of the industry 2015 9
0
20
40
60
80
100
120
140
160
180
200
Year
Tota
l R&
D s
pend
ing
($ m
illio
ns)
20082004 2006 2010 2012 2014 2016
Months
Max
Mean
Median
Minimum0 10 20 30 40 50 60 70
Months of cash available
Tota
l per
cent
age
(%) o
f com
pani
es
0%
5%
10%
15%
20%
25%
30%
35%
0 – 4 5 – 8 9 – 12 > 12
Research and development spending
How much is your company spending on research and development?
There has been a decline recently in the level of investment in research and development in Alberta’s life sciences sector. This may be due to a drop in the number of human therapeutic development companies, which tend to spend much more on research and development than the growing device, natural health and nutraceutical companies.
How many months of cash do you have available?
Months of cash on hand
A number of stable and mature companies have sufficient cash on hand to fund operations. However, the challenges of raising capital continue to be a major focus for management in development-stage companies.
$135 $136.7
$128.8
$181.9
$175.6
$132.3
$108.6
6
10
60
0
30%
26%24%
20%
10
Average number of employees
Tota
l per
cent
age
(%)
0%
10%
20%
30%
40%
50%
60%
1 to 7 8 to 15 16 to 30 31 to 50 51 to 100 over 100
Year
Num
ber
of e
mpl
oyee
s
0
1,000
2,000
3,000
4,000
5,000
6,000
2004 2006 2008 2010 2012 2014 2015(expected)
Human resources
Very few companies (6%) have more than 100 employees, indicating that this industry is a high growth area with few major mature companies.
In 2014, what was the average number of people employed at your company?
The largest segment of companies employed fewer than eight people (51%). This is reflective of the number of start-ups and very small owner-managed businesses that are the future of the industry in Alberta. Very few companies (6%) have more than 100 employees, indicating that this industry is a high growth area with few major mature companies.
How many people did you employ in your company in 2014 and what are your expectations for 2015?
Employment figures are trending upward for the industry in Alberta, both at a current level and a future expected level. These jobs are mostly high-paying positions for people with significant levels of education who bring value, knowledge and innovation to the marketplace. Assuming an indirect economic multiplier of four, the life sciences industry contributed approximately 18,000 jobs in Alberta in 2014.
51%
22%
12%
6%3%
6%
3,316
4,793 4,5074,084
3,532
4,4774,610
Life sciences in Alberta State of the industry 2015 11
PhD degree
58%
36%
7%
Masters degree
Bachelors degree
Post secondary diploma
High school diploma
Chief executive officer
58%
36%
7%
Chief financial officer
Chief scientific officer
Business development and sales
Regulatory affairs
Clinical and medical development
Manufacturing
Engineering
Other
What percentage of your employees have a high school diploma, a post-secondary degree, or some other form of post-secondary education?
The life sciences industry continues to provide employment and entrepreneurial opportunities for a highly educated work force. The significant proportion of PhDs and Masters degrees in the industry speaks to a strong depth of knowledge that will continue to enable the growth of the industry and the attraction of additional professionals to Alberta.
Which of the following executive positions are the most challenging for your company to fill?
The highly specialized skills of business development executives and regulatory affairs personnel continue to be the hardest to find for life sciences companies in Alberta.
38%
15%
22%
14%
11% 8%
10%
9%
9%
9%35%
6%
6%
8%
12
0%
5%
10%
15%
20%
25%
30%
Tota
l per
cent
age
(%) o
f res
pond
ents
Revenues ($ millions)
0 to 0.5 0.5 to 1 1 to 5 5 to 10 10 to 20 20 to 50 > 50
35%
Alberta
58%
36%
7%
Rest of Canada
USA
Eurpoe
Asia
Other
Year
0
200
400
600
800
1,000
1,200
1,400
2006 2008 2010
Tota
l rev
enue
s ($
mill
ions
)
2012 2014 2015forecast
Revenue
What is your reported revenue (product, sales and services) for your fiscal year ending in 2014?
A small number of companies have annual revenues greater than $50 million, but the majority had annual 2014 revenues of $5 million and under (72%). This is consistent with the distribution of the number of employees in an earlier chart in this report, found on page 10.
What were your revenues for 2014 and forecast for 2015?
The industry generated more than $1 billion in revenues in 2014 and companies are optimistic that this will increase in 2015 by a significant factor.
What percentage of your 2014 fiscal revenue was earned in each of the following regions?
As we might expect, companies earned the largest share of their revenues in Alberta. Companies also competed strongly in international markets, generating significant revenues especially in the United States and Europe.
31%
14%
27%
12%8%
3%5%
$1,210.5
$814.0
$1,242.6
$748.8
$977.4 $1,063.5
6%
7%
8%
31%16%
32%
Life sciences in Alberta State of the industry 2015 13
0
25
50
100
150
200
Year
Cap
ital r
aise
d ($
mill
ions
)
2004 2006 2008 2010 2012 2014 2015(estimated)
How much capital did you raise in the fiscal year ending in 2014 and estimate raising in 2015?
Alberta companies in 2014 increased the amount of capital they were able to raise. However, compared to other regions of Canada and the United States, the amount of capital is disproportionately lower when compared to the number of companies, the number of employees and revenues generated. This has been a major challenge for Alberta-based development companies in particular. For example, Alberta saw a total of 14 VC deals in 2014 valued at a combined $52 million, whereas British Columbia realized 72 deals worth a combined $554 million1.
1 Canadian Venture Capital & Private Equity Association. “2014 Canadian Venture Capital Market Overview.” http://www.cvca.ca/wp-content/uploads/2014/07/CVCA-2014-VC-data-deck1.pdf. Accessed September 2, 2015.
Compared to other regions of Canada and the United States, the amount of capital is disproportionately lower when compared to the number of companies, the number of employees and revenues generated.
$112.0 $117.0
$101.0
$131.7$137.4
$175.7
$163.5
14
Tota
l per
cent
age
(%)
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
Gov
ernm
ent
faci
litat
edpr
ogra
ms
Foun
der
equi
ty
Ang
elin
vest
ors
Fam
ily &
frie
nds
Cor
pora
tein
vest
ors
Deb
t
Publ
icfin
anci
ng
Ven
ture
capi
talis
ts
Inst
itutio
nal
Acq
uisi
tions
& d
ives
titur
es
Oth
er
Tota
l per
cent
age
(%)
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
Gov
ernm
ent
faci
litat
edpr
ogra
ms
Foun
der
equi
ty
Ang
elin
vest
ors
Deb
t
Cor
pora
tein
vest
ors
Fam
ily &
frie
nds
Publ
icfin
anci
ng
Ven
ture
capi
talis
ts
Inst
itutio
nal
Acq
uisi
tions
& d
ives
titur
es
Oth
er
Financing
Which sources did you use to raise capital in 2014?
Government-backed funding programs continue to be the most significant source of capital for the industry, followed by founders’ capital and angel investors. This points to the limited amount of venture capital and initial public offerings in Alberta as compared to other regions of Canada and the United States.
Which sources of capital do you intend to pursue in the future?
The expected future sources of capital are fairly consistent with recent history. This is consistent with the continuing lack of institutional and venture capital investors focused on the life sciences industry in Alberta.
Note: the percentages in these charts sum to greater than 100% because many companies accessed capital from more than one source.
42.86%
34.92%
22.22%20.63%
4.76% 6.35%7.94%
1.59%
14.29%
0.00%
22.22%
56.16%
24.66%
31.51%
20.55%23.29%
20.55%
26.03%
13.7% 13.7% 12.33% 12.33%
Life sciences in Alberta State of the industry 2015 15
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
Oth
er
Alb
erta
Inno
vate
s- T
echn
olog
y Fu
ture
s V
ouch
er P
rogr
am (P
revi
ousl
y A
E&T)
Alb
erta
Inno
vate
s -
Hea
lth S
olut
ions
(Pre
viou
sly
AH
FMR)
Alb
erta
Inno
vate
s- T
echn
olog
y Fu
ture
s A
ssoc
iate
s Pr
ogra
m (P
revi
ous
Inge
nuity
Ass
ocia
tes)
Alb
erta
Inno
vate
s- B
io S
olut
ion
Can
adia
n In
stitu
tes
of H
ealth
Res
earc
h (C
IHR)
Bio
Alb
erta
Med
ical
Pro
duct
D
evel
opm
ent
Prog
ram
(MPD
P)
AV
AC
Indu
stria
l Res
earc
h A
ssis
tanc
e Pr
ogra
m (I
RAP)
Inte
rnat
iona
l Sci
ence
and
Tec
hnol
ogy
Part
ners
hips
Can
ada
Prog
ram
(IST
PP)
Scie
ntifi
c Ex
perim
enta
l D
evel
opm
ent
prog
ram
Clim
ate
Cha
nge
Emis
sion
Man
agem
ent
Cor
pora
tion
(CC
EMC
)
Sust
aina
ble
Dev
elop
men
t Te
chno
logy
Can
ada
(SD
TC)
Bioe
nerg
y Pr
oduc
er C
redi
t Pr
ogra
m
Which governmental support initiatives have you used?
The largest sources of government financing were from the Industrial Resource Assistance (IRAP) and Scientific Research & Experimental Development (SR&ED) programs. The Alberta Innovates Technology Futures (AITF) voucher program and the AITF Associates program were the next most actively accessed sources of funding for Alberta’s life sciences companies.
Note: the percentages of all the categories adds up to a figure greater than 100% because many companies accessed more than one source of government financing.
18.07%
19.28%
37.35%33.73%
8.43%13.25% 13.25%
10.84%
73.49%
61.45%
3.61%4.82% 2.41%4.82%
16
This page has intentionally been left blank.
Life sciences in Alberta State of the industry 2015 17
Issues facing the industry
Globally, the life sciences industry offers tremendous economic potential. In Alberta, the industry delivers economic diversification; it attracts and retains highly educated people; and it promotes intellectual property development in the province. Albertans benefit when the rate of technological development and commercialization can compete with other global jurisdictions. The life sciences industry is already making a substantial contribution to the province’s research and development capability, intellectual capital and high technology economy. As the capacity for commercialization of life sciences products and services grows in Alberta, the industry will move closer to achieving its full potential. There has been an intentional effort to increase the effectiveness of industry and the healthcare system working together. Examples of this include Alberta Health’s “Health Technology Assessment and Innovation” process and the ongoing efforts by Alberta Health Services to make it easier for companies to do clinical trials in Alberta.
The innovation system is positioned to assist industry along its path to growth and, with its targeted policies and activities, contribute to accelerated development and success. The following are key areas of importance to companies that can boost their growth.
The top 3 most important issues for the industry are:
1. Improving the investment climate and funding opportunities
2. Continuing to improve tax based incentives for companies, including Angel tax incentives and flow-through shares
3. Adding sustainable funding sources, such as a Small Business Innovation Research (SBIR) program
Improving the investment climate and funding opportunities, continuing to improve tax based incentives for companies (including Angel tax incentives and flow-through shares), and adding sustainable funding sources (such as a Small Business Innovation Research program) are the top three initiatives that would assist companies to expedite their growth.
18
0 10 20 30 40 50 60 70 80 90 100
Streamline immigration efforts and programs to make attraction of qualified personnel easier
Introduce life sciences in cross-curricular learning from grades 7-12
Government and industry partnerships to increase the availability of highly qualified personnel (e.g. internships)
Funding programs for labor training to attract and retain highly skilled workforce for Life Science SMES
Better environment for conducting clinical trials in Alberta
Enhance technology transfer from universities, colleges and institutions
Enhance established funding programs (e.g. vouchers, AVAC)
Introduce an SBIR (Small Business Innovation Research Program)
Improve investment climate through globally competitive mechanisms such as matching funding models and enhanced venture capital environment
Introduce an Angel tax incentive
Introduce flow-through shares
Support life sciences through tax based instruments
Sustainable funding for research and commercialization
Build a supportive environment for innovation and commercialization
Access to highly qualified personnel
Very important Important Not important Not applicable
Streamlined application process for all provincial life science funding programs
Better access to the local market for our companies
Importance placed on the following issues:
42.3
40.8
57.6
51
34
32.2
43.4
17
14.8
24.4
31.9
44.5
42.3
28.2
31.5
39.7
25
31.5
32.9
38.7
31.5
30.8
34
46.8
37.23
31.5
17.3
11.9
9.6
11.9
9.7
19.1
10.7
5.4
18
22.3
11.7
12.7
18.4
9.7
14.1
9.6
5.4
7.6
13.8
18.2
19.5
34
28.7
17
18.1
7.6
n o t e s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20
Industry participation BioAlberta and Deloitte would like to thank all of the survey participants who agreed to be acknowledged in this report.
Accumol Inc.
Adaptive Engineering Inc.
Afinity Life Sciences Inc.
Akshaya Bio Inc.
Alberta Research Chemicals Inc.
Alzheimer’s Innovation Institute Inc.
Angeltear Solutions Inc.
Aqua Air Systems Ltd.
Aquila Diagnostic Systems Inc.
Artsinteg Corporation
Associated Health Systems Inc.
ATI-Composites Canada Inc.
ATS ventures Inc.
Bertech Pharma Ltd.
Best Environmental Technologies Inc.
Biolipids Inc.
Biomotion Ltd.
BioNeutra North America
BioRefinex Canada Inc.
Bortec Biomedical Ltd.
Calgary Scientific Inc.
Campbell Scientific (Canada) Corp.
Canadian Bio-Systems Inc.
Canadian Greenfield Technologies
Centurion Medical Corporation
ChemRoutes Corporation
Classic Health Supplies Ltd.
ClearView Biostructures Inc.
Colman Prosthetics Orthotics Ltd.
CQI Consulting Ltd.
Dalynn Biologicals Inc.
Delta Genomics Centre
Detectit
DriveABLE Assessment Centres Inc.
DynaLIFEDx
Epsilon Chemicals Ltd.
Exciton Technologies Inc.
FameBioRefinery
Fytozimus Biotech Inc.
General Intermediates of Canada
Gilead Alberta ULC
GrowSafe Systems Ltd.
H3ALTH TECHNOLOGIES INC.
Himark Biogas Inc.
Imaging Dynamics Company Ltd. (IDC)
IMBiotechnologies Ltd.
Innovotech Inc.
IntelligentNano Inc.
Kent Imaging
KMT Hepatech Inc.
Lambert Radiation Shielding
Luxmux Technology Corporation
Medical Bionics Inc.
Metabolic Modulators Research Ltd.
Metabolistics Inc.
Metabolomic Technologies Inc.
MPowRX Health and Wellness Products Inc.
Mustus Energy Ltd.
Nanalysis Corp.
Neuro Investigations Inc.
Nova Green
Oncolytics Biotech Inc.
Orpyx Medical Technologies Inc.
Osteometabolix Pharmaceuticals Inc.
Parvus Therapeutics Inc.
PBR Laboratories Inc.
Permolex Ltd.
Prairie Biogas
Prev Biotech Inc.
priMED Medical Products Inc.
Progressive Optical Research Ltd.
Prosthetic Concepts
Q-Chuck Technologies Inc.
Quest PharmaTech Inc.
Radient Technologies Inc.
RadTag Technologies Inc.
Saf-T-Pak Inc.
Sagatech Electronics Inc.
Sage Biosciences Inc.
SBI BioEnergy
Seed Check Technologies Inc.
SinoVeda Canada Inc.
SolAeroMed Inc.
Stream
Symbiotic EnviroTek Inc.
Taiga BioActives Inc.
TC Scientific Inc.
Technology North Corporation
Tenby Medical, A Division of Pekisko Holdings Inc.
The Litebook Company Ltd.
Thermotex Therapy Systems Ltd.
Transcriptome Sciences Inc.
Troppman Prosthetics Ltd
Tyler Research Corp.
Verdant Energy Ltd.
Vista Technology Inc.
XORTX Pharma Corp.
XSENSOR Technology Corp.
Life sciences in Alberta State of the industry 2015 21
Need more information?
BioAlberta
BioAlberta has been the central voice and organizing hub for the life sciences industry in Alberta since 1999. It is a private, not-for-profit industry association with more than 140 members. The association’s activities are focused on advocacy, promotion and networking, and industry development. In its advocacy efforts on the national stage, BioAlberta joins forces with other life sciences organizations such as its counterparts in other provinces and BIOTECanada.
Contact:Mel WongPresident, [email protected]
About Deloitte’s Life Sciences practice
Deloitte professionals have experience working with life sciences companies across the country and globally to assess their strategic options; assist in forming, establishing and maintaining partnerships and alliances; develop commercialization strategies; enhance revenues; improve operating efficiencies; optimize asset utilization; strengthen management teams; provide due diligence and valuation support as part of a transaction; implement tax efficient structures; streamline the complexities related to industry auditing and accounting; mitigation enterprise risk; and provide negotiation and advisory assistance.
For more information about how Deloitte can help your organization, contact the Life Sciences leadership team:
Jeremy WebsterNational biotechnology leader780-915-0183 [email protected]
Bill StamatisNational life sciences [email protected]
www.deloitte.ca
Deloitte, one of Canada’s leading professional services firms, provides audit, tax, consulting, and financial advisory services. Deloitte LLP, an Ontario limited liability partnership, is the Canadian member firm of Deloitte Touche Tohmatsu Limited.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms.
© Deloitte LLP and affiliated entities.Designed and produced by the Deloitte Design Studio, Canada. 15-3210H